5/31/2013

Scynexis secured global rights to develop and market Merck's oral glucan synthase inhibitor MK-3118 as a treatment for systemic fungal diseases. The compound is set to begin Phase IIb studies. The deal entitles Merck to milestone fees and sales royalties.

Related Summaries